Turbocharge the Development of Best-in-Class Antibody & Cell-Based Approaches of Innate Immune Therapies, to Launch Safe, Globally Scalable & Efficacious Therapies from Europe The momentum of innate immune cell R&D is growing exponentially to harness innate immune responses in oncology, realise scaled allogeneic manufacturing, and drive commercial
18-20 October 2022